Abstract
Because of the ICD-10 disease coding system transition that occurred in the United
States in 2015, coding and billing for services on behalf of patients who experience
cochlear and/or vestibular toxicity may be daunting and misunderstood. Coding and
billing for any audiology procedure can be compelling; choosing the appropriate codes
for these specific patients is critical not only for payment for services rendered
but also for the national and global implications, given their utilization is tracked
for mortality and morbidity statistics and potential policies.
Keywords
ototoxic hearing loss - anti-neoplastics - aminoglycosides - medical record documentation
